erlotinib hydrochloride has been researched along with podophyllotoxin in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (podophyllotoxin) | Trials (podophyllotoxin) | Recent Studies (post-2010) (podophyllotoxin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,119 | 226 | 782 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | podophyllotoxin (IC50) |
|---|---|---|---|
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 2.145 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 0.6733 | |
| Tubulin beta chain | Sus scrofa (pig) | 0.622 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.014 | |
| Tubulin beta-4A chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta chain | Homo sapiens (human) | 1.7233 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.6 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 1.7233 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 5 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 1.7233 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 1.7233 | |
| Calcium-activated potassium channel subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.56 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 0.8685 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 1.7233 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 1.7233 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 0.907 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 0.7744 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 1.7233 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
1 review(s) available for erlotinib hydrochloride and podophyllotoxin
| Article | Year |
|---|---|
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
1 other study(ies) available for erlotinib hydrochloride and podophyllotoxin
| Article | Year |
|---|---|
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |